Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.56 Billion SEK | 31.94% |
| 2022 | 1.18 Billion SEK | 162.76% |
| 2021 | 451.62 Million SEK | 80.54% |
| 2020 | 250.15 Million SEK | 337.87% |
| 2019 | 57.12 Million SEK | 88.91% |
| 2018 | 30.24 Million SEK | 3.88% |
| 2017 | 29.11 Million SEK | -29.89% |
| 2016 | 41.52 Million SEK | 313.51% |
| 2015 | 10.04 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.56 Billion SEK | 0.15% |
| 2024 Q2 | 1.64 Billion SEK | 4.61% |
| 2023 FY | 1.56 Billion SEK | 31.94% |
| 2023 Q3 | 1.25 Billion SEK | 4.54% |
| 2023 Q2 | 1.2 Billion SEK | 0.46% |
| 2023 Q1 | 1.19 Billion SEK | 1.06% |
| 2023 Q4 | 1.56 Billion SEK | 24.32% |
| 2022 Q2 | 737.19 Million SEK | 55.79% |
| 2022 FY | 1.18 Billion SEK | 162.76% |
| 2022 Q1 | 473.19 Million SEK | 4.78% |
| 2022 Q3 | 792.17 Million SEK | 7.46% |
| 2022 Q4 | 1.18 Billion SEK | 49.8% |
| 2021 Q1 | 254.55 Million SEK | 1.76% |
| 2021 FY | 451.62 Million SEK | 80.54% |
| 2021 Q4 | 451.62 Million SEK | -5.54% |
| 2021 Q3 | 478.13 Million SEK | 83.3% |
| 2021 Q2 | 260.85 Million SEK | 2.48% |
| 2020 Q1 | 59.73 Million SEK | 4.56% |
| 2020 Q2 | 61.79 Million SEK | 3.46% |
| 2020 FY | 250.15 Million SEK | 337.87% |
| 2020 Q4 | 250.15 Million SEK | 294.59% |
| 2020 Q3 | 63.39 Million SEK | 2.59% |
| 2019 Q1 | 29.58 Million SEK | -2.16% |
| 2019 Q4 | 57.12 Million SEK | 85.01% |
| 2019 Q3 | 30.87 Million SEK | -34.93% |
| 2019 Q2 | 47.45 Million SEK | 60.37% |
| 2019 FY | 57.12 Million SEK | 88.91% |
| 2018 FY | 30.24 Million SEK | 3.88% |
| 2018 Q4 | 30.24 Million SEK | 6.99% |
| 2018 Q2 | 59.33 Million SEK | 84.9% |
| 2018 Q1 | 32.08 Million SEK | 10.23% |
| 2018 Q3 | 28.26 Million SEK | -52.36% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | 29.11 Million SEK | 0.0% |
| 2017 FY | 29.11 Million SEK | -29.89% |
| 2016 FY | 41.52 Million SEK | 313.51% |
| 2015 FY | 10.04 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 4.42 Million SEK | -35276.028% |
| BioArctic AB (publ) | 139.5 Million SEK | -1022.372% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -66273.167% |
| CombiGene AB (publ) | 4.15 Million SEK | -37574.287% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -2101.613% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -11269.383% |
| OncoZenge AB (publ) | 1.69 Million SEK | -92056.739% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -1368.871% |
| Mendus AB (publ) | 51.22 Million SEK | -2956.599% |
| LIDDS AB (publ) | 3.75 Million SEK | -41586.448% |
| Lipum AB (publ) | 7.53 Million SEK | -20671.332% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -1162.91% |
| Simris Alg AB (publ) | 148.93 Million SEK | -951.272% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -13319.121% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -30039.753% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | -224.726% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -2079.183% |
| Ziccum AB (publ) | 6.38 Million SEK | -24410.692% |
| AcouSort AB (publ) | 10.37 Million SEK | -14987.136% |
| Active Biotech AB (publ) | 13.4 Million SEK | -11584.649% |
| Alzinova AB (publ) | 9.33 Million SEK | -16680.013% |
| Amniotics AB (publ) | 10.54 Million SEK | -14745.387% |
| Camurus AB (publ) | 414.81 Million SEK | -277.452% |
| Cantargia AB (publ) | 54.97 Million SEK | -2748.359% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -40695.805% |
| Genovis AB (publ.) | 98.04 Million SEK | -1496.931% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -8366.221% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -8070.231% |
| Intervacc AB (publ) | 21.68 Million SEK | -7122.062% |
| Kancera AB (publ) | 17.97 Million SEK | -8609.217% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -13433.953% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -30255.622% |
| NextCell Pharma AB | 13.68 Million SEK | -11337.919% |
| Saniona AB (publ) | 86.08 Million SEK | -1718.876% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -3732.064% |
| Xintela AB (publ) | 14.01 Million SEK | -11071.909% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -4424.876% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -5762.449% |
| Corline Biomedical AB | 6.78 Million SEK | -22962.94% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -2451.857% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -9614.854% |
| Aptahem AB (publ) | 8.99 Million SEK | -17301.346% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -3290.522% |
| Fluicell AB (publ) | 8.91 Million SEK | -17463.017% |
| Biovica International AB (publ) | 34.76 Million SEK | -4403.532% |
| Abliva AB (publ) | 16.78 Million SEK | -9230.451% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | -629.61% |
| 2cureX AB (publ) | 2.93 Million SEK | -53247.291% |
| I-Tech AB | 16.2 Million SEK | -9562.099% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | -32.028% |
| Cyxone AB (publ) | 4.69 Million SEK | -33256.263% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -11647.772% |
| Biosergen AB | 5.08 Million SEK | -30691.406% |
| Nanologica AB (publ) | 79.32 Million SEK | -1873.783% |
| SynAct Pharma AB | 51.83 Million SEK | -2920.687% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -19597.358% |
| BioInvent International AB (publ) | 90.45 Million SEK | -1631.002% |
| Oncopeptides AB (publ) | 181.59 Million SEK | -762.203% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -87176.644% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -12186.119% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -21466.708% |